Clinical Trial

Hypofractionated Radiosurgery for Localised Prostate Cancer (HYPOSTAT-III)

Study acronym: HYPOSTAT-III
Recruiting
View on ClinicalTrials.gov →
Summary
Hypofractionated radiosurgery with 5 fractions is considered standard of care for localized prostate cancer. The investigators initiated this multicenter phase II prospective trial to analyse feasibility (toxicity) of hypofractionated radiosurgery with 3 fractions in patients with localised prostate cancer under the hypothesis that the ratio of patients with late GU and GI toxicity ≥ grade 2 after 1 year amounts to 8.4% and 1.3% and is significant lower than 16.4% and 5.7% currently.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-31; most recent amendment 2026-04-28.
Status change: Not Yet Recruiting → Recruiting 2026-04-28
Trial Details
NCT Number NCT06914544
Lead Sponsor University Hospital Schleswig-Holstein
Collaborators: University of Luebeck
Conditions Prostate Cancer
Enrollment 175 participants
Start Date 2025-12-10
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-29